Gyre Therapeutics (GYRE) Income from Non-Controlling Interests (2023 - 2026)

Gyre Therapeutics (GYRE) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 212.64% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 40.4% YoY) and the FY2025 annual result came in at $4.9 million, down 16.51% from the prior year.
• Income from Non-Controlling Interests fell to -$1.2 million in Q1 2026 per GYRE's latest filing, from $357000.0 in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $3.5 million in Q3 2023 and bottomed at -$1.2 million in Q1 2026.
• The 4-year median for Income from Non-Controlling Interests is $1.1 million (2025), against an average of $1.3 million.
• The widest annual swing landed in 2024, when Income from Non-Controlling Interests jumped 2203.45%; it then slumped 212.64% in 2026.
• Tracing GYRE's Income from Non-Controlling Interests over 4 years: stood at $29000.0 in 2023, then jumped by 2203.45% to $668000.0 in 2024, then slumped by 46.56% to $357000.0 in 2025, then slumped by 426.89% to -$1.2 million in 2026.
• Per Business Quant, the three latest GYRE Income from Non-Controlling Interests figures stand at -$1.2 million (Q1 2026), $357000.0 (Q4 2025), and $2.3 million (Q3 2025).

Peer Comparison